First Business Financial Services Inc. Cuts Stock Position in Cencora, Inc. $COR

First Business Financial Services Inc. lessened its position in shares of Cencora, Inc. (NYSE:COR) by 14.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,344 shares of the company’s stock after selling 2,268 shares during the quarter. Cencora comprises 0.4% of First Business Financial Services Inc.’s holdings, making the stock its 27th biggest position. First Business Financial Services Inc.’s holdings in Cencora were worth $4,170,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC increased its position in shares of Cencora by 70.0% during the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after purchasing an additional 35 shares in the last quarter. Vermillion & White Wealth Management Group LLC grew its stake in Cencora by 69.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after buying an additional 43 shares during the last quarter. Caldwell Trust Co purchased a new position in Cencora during the 2nd quarter worth $46,000. Salomon & Ludwin LLC raised its stake in Cencora by 638.1% in the third quarter. Salomon & Ludwin LLC now owns 155 shares of the company’s stock valued at $47,000 after buying an additional 134 shares during the last quarter. Finally, Capital A Wealth Management LLC boosted its holdings in Cencora by 3,975.0% in the second quarter. Capital A Wealth Management LLC now owns 163 shares of the company’s stock worth $49,000 after acquiring an additional 159 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Stock Performance

NYSE COR opened at $351.72 on Thursday. The stock has a market capitalization of $68.23 billion, a price-to-earnings ratio of 44.24, a PEG ratio of 1.67 and a beta of 0.66. The stock has a 50-day moving average of $348.92 and a 200 day moving average of $321.33. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32. Cencora, Inc. has a twelve month low of $237.71 and a twelve month high of $377.54.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The business had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. During the same period in the previous year, the business earned $3.34 earnings per share. The business’s revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Sell-side analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. This is a positive change from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date was Friday, November 14th. Cencora’s dividend payout ratio (DPR) is 30.19%.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on COR. TD Cowen upped their price objective on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, November 10th. Wall Street Zen cut shares of Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. Mizuho lifted their price objective on shares of Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Jefferies Financial Group set a $440.00 target price on Cencora in a research report on Thursday. Finally, Barclays began coverage on Cencora in a research report on Monday, December 8th. They set an “overweight” rating and a $400.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $393.08.

Insider Transactions at Cencora

In other news, EVP Silvana Battaglia sold 1,677 shares of Cencora stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the sale, the executive vice president directly owned 18,796 shares of the company’s stock, valued at $6,484,620. The trade was a 8.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $343.45, for a total value of $1,750,221.20. Following the completion of the transaction, the chief executive officer owned 68,059 shares in the company, valued at $23,374,863.55. The trade was a 6.97% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 15,220 shares of company stock valued at $5,343,561 over the last 90 days. Corporate insiders own 10.80% of the company’s stock.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.